Uncategorized

The FDA first issued a warning regarding the risk of serious liver injury with Ocaliva in September 2017. In early […]

This webinar explores key trends shaping the pharmaceutical industry’s future featured in Clarivate’s 2025 Drugs to Watch™ report. Industry experts

According to her complaint, Paulsen began receiving injections of Depo-Provera in 1998 and continued to receive the quarterly birth control

With over 20 years of experience in the biopharmaceutical industry and life sciences consulting, Dee Chaudhary, a Principal at Clarivate

Given common questions raised in the litigation, all of the lawsuits are currently centralized before U.S. District Judge Allison D.

Streamline your literature management workflows with cutting-edge tools designed for pharma R&D teams. This webinar, hosted by Jill Shuman, MS,

As part of the coordinated management of the litigation, the parties are currently engaged in a discovery process that will

For all the consumer-facing headlines of generative AI’s healthcare failures—some less serious, others more troubling—a contrast is unfolding in the greater

Suboxone (buprenorphine and naloxone) was approved by the FDA in 2002, for treatment of recovering opioid addicts, helping them avoid

Pharmaceutical Marketing Evolved Transform your DTC marketing with AI-powered precision targeting. Drive better patient outcomes and commercial success through privacy-safe